Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.

This Article contains errors in the Acknowledgements section.

“The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926).”

should read:

“The authors acknowledge funding support from the National Health and Medical Research Council of Australia (1004926) and Diabetes Australia.”